SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gordon James who wrote (255)8/23/1999 11:23:00 AM
From: Gordon James  Read Replies (1) of 666
 
P.S. regarding HAMA and first-line treatment,

I suppose it's not necessarily the case that a possible inability to adequately control HAMA in first-line Bexxar treatment would preclude widespread use of first-line Bexxar - if we were to find through analysis of results that patients' long-term survival was improved with first-line Bexxar vs. not using it first-line, then it might be determined that the increased risk of HAMA preventing subsequent Bexxar treatments would be outweighed by the survival benefit. So this would perhaps end up being more of a problem for CLTR and it's shareholders than for patients (less Bexxar sales for re-treatment). Still seems a less likely scenario to me, but possible I'm sure...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News